Freshfields-Led Sanofi Wraps Up $470M Vigil Buy
Sanofi said Wednesday that it has completed the approximately $470 million acquisition of U.S. biotechnology company Vigil Neuroscience, which specializes in neurodegenerative diseases, strengthening the French pharma titan's early-stage medicine pipeline...To view the full article, register now.
Already a subscriber? Click here to view full article